Table IV. Examples of Ab combinations and association with risk of malaria.

Combinations	uHR (95% CI)	p Value
Additive combinations (n = 10)
MSP3/GLURP	0.31 (0.11–0.92)	0.035
Rh5/MSP2	0.15 (0.04–0.65)	0.011
Rh5/AMA1	0.16 (0.04–0.71)	0.015
Rh5/MSP1-19	0.17 (0.04–0.72)	0.016
Rh5/EBA175F2	0.14 (0.03–0.59)	0.007
Rh5/EBA175RIII-V	0.13 (0.03–0.54)	0.005
AMA1/MSP2	0.28 (0.08–0.98)	0.047
EBA175RIII-V/Rh2-2030/Rh4.2	0.06 (0.01–0.46)	0.007
EBA140RIII-V/Rh2-2030/Rh4.2	0.06 (0.01–0.47)	0.007
EBA140RIII-V/Rh4.2	0.07 (0.01–0.49)	0.008
Nonadditive combinations (n = 10)
MSP1-19/MSP2	0.47 (0.17–1.27)	0.135
MSP2/MSP3	0.46 (0.17–1.25)	0.129
MSP1-19/AMA1	0.47 (0.19–1.19)	0.112
AMA1/MSP1-19/MSP2	0.43 (0.16–1.14)	0.09
Rh5/Ripr	0.26 (0.09–0.76)	0.014
EBA175RIII-V/Rh4.2	0.12 (0.03–0.51)	0.004
Rh2-2030/Rh4.2	0.15 (0.04–0.65)	0.011
EBA140RII/Rh2-2030/Rh4.2	0.15 (0.03–0.63)	0.010
EBA175F2/MSP1-19	0.38 (0.14–1.03)	0.057
MSP1-19/AMA1/EBA175F2	0.27 (0.09–0.79)	0.017

Combined responses were examined using a summation of quartile responses (0, 1, 2, and 3, representing low to high) for each group. These combinations were then used to create three equal groups reflecting low-, intermediate-, and high-response scores. uHRs were calculated using Cox-regression comparing those with high versus low responses with the risk for symptomatic malaria over 6 mo of follow-up, with the analysis based on the first symptomatic episode only. Results for all Ab combinations that were assessed in this study are shown in Supplemental Table III. Examples shown represent 10 combinations with the strongest additive effect (additive combinations) and 10 representative examples of nonadditive combinations.

CI, Confidence interval.